Oestrogen receptor beta: what it means for patients with breast cancer.
Oestrogen receptor (ER) alpha is a well established prognostic marker in breast cancer, and all patients who are ER alpha positive receive tamoxifen as adjuvant endocrine therapy. Although ER alpha predicts a favourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer.
Molecular Medicine Unit, University of Leeds, Leeds, UK. v.speors@leeds.ac.uk
Valerie
V
Speirs
Pauline J
PJ
Carder
Sally
S
Lane
David
D
Dodwell
Mark R J
MR
Lansdown
Andrew M
AM
Hanby
D014408:Biomarkers, Tumor / Q000266:history / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D047629:Estrogen Receptor beta; D005260:Female; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007150:Immunohistochemistry; D011379:Prognosis; D020033:Protein Isoforms; D011960:Receptors, Estrogen / Q000266:history / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D014408:Biomarkers, Tumor; D047629:Estrogen Receptor beta; D020033:Protein Isoforms; D011960:Receptors, Estrogen